The basic underlying pathophysiological processes underlying the major complications of hypertension (that is, heart attacks and strokes) are thrombogenesis and atherogenesis. Indeed, despite the blood vessels being exposed to high pressures in hypertension, the complications of hypertension are paradoxically thrombotic in nature rather than haemorrhagic. The evidence suggests that hypertension appears to confer a prothrombotic or hypercoagulable state, which can be
Introduction
Hypertension is well-recognised to be an important contributor to heart attacks and stroke. 1 Furthermore, effective antihypertensive therapy reduces strokes by 30-40%, and coronary artery disease by approximately 25%. 2 Nevertheless the basic underlying pathophysiological processes underlying both of these major complications of hypertension are thrombogenesis and atherogenesis. Indeed, despite the blood vessels being exposed to high pressures in hypertension, the complications of hypertension are paradoxically thrombotic in nature rather than haemorrhagic. Whilst much attention has been focused on the renin-angiotensin system, cathecholamines and other neurohormonal mechanisms involved in the pathogenesis of hypertension, the study of the prothrombotic state in hypertension has been relatively neglected.
Over 150 years ago, Virchow postulated that three features predispose to thrombus formation, that is, abnormalities in blood flow, blood constituents and the vessel wall. 3 Whilst Virchow was referring to venous thrombosis, the concepts can be applied to arterial thrombosis. An update of Virchow's triad for thrombogenesis for the new millennium can be considered by reference to abnormalities of haemorheology and turbulence at bifurcations and stenotic regions (that is, 'abnormal blood flow'), abnormalities in platelets as well as the coagulation and fibrinolytic pathways ('abnormal blood constituents') and finally, abnormalities in the endothelium ('abnormal vessel wall').
Indeed, patients with hypertension are well-recognised to demonstrate abnormalities of each of these components of Virchow's triad, leading to a prothrombotic or hypercoagulable state. 4 Furthermore, the processes of thrombogenesis and atherogenesis are intimately related, and many of the basic concepts thrombogenesis can be applied to atherogenesis. Importantly, recent improvements in biochemical techniques have enabled us to quantify different components of both these processes.
Evidence for the prothrombotic state in hypertension
Evidence for the hypercoagulable state in hypertension has been extensively reviewed. [4] [5] [6] Indeed, evidence from numerous epidemiological, 7-9 crosssectional 10, 11 and cohort studies 12, 13 have reported abnormalities in the coagulation and fibrinolytic pathways, as well as in platelets and the endothelium.
Relation to conventional risk factors
These abnormalities in haemostasis appear to be additive to conventional risk factors for cardiovascular and cerebrovascular events. For example, in the ECAT study, high plasma fibrinogen in association with high serum cholesterol was associated with the highest risk for cardiovascular events.
14 The interaction between plasma fibrinogen and cholesterol levels is also demonstrated in the Leigh Study, where the incidence of heart attacks was six times greater in those with high plasma fibrinogen (у3.5 g/l) and cholesterol levels (у6.2 mmol/l), when compared to those with low fibrinogen (Ͻ3.5 g/l) levels. 15 Other risk factors, such as smoking and diabetes, markedly influence the prothrombotic state and are probably additive to the intrinsic Journal of Human Hypertension abnormalities (and cardiovascular risk) seen in hypertensives.
Association with target organ damage
The abnormalities in haemostasis in hypertensives can be related to target organ damage, such as the presence of left ventricular hypertrophy on echocardiography. 10 The latter is a powerful predictor of cardiovascular events, with an eight-fold increase in the risk of stroke and a four-fold increase in the risk of coronary artery disease. The presence of left ventricular hypertrophy (LVH) is also an independent contributor to the risk of stroke in atrial fibrillation. 16 Furthermore, high von Willebrand factor levels, an established index of endothelial damage or dysfunction can be related to microalbuminuria (defined as the excretion of urine albumin between 20 and 200 mcg/min), another surrogate manifestation of hypertensive target organ damage. 17 The abnormalities in various indices can perhaps be related to the degree, and possibly the duration of hypertension, and those with mild hypertension or lower blood pressures, and more recent onset hypertension (which is usually more difficult to precisely quantify) may show less abnormalities in the prothrombotic state. For example, patients with severe hypertension (defined as Ͼ160/95 mm Hg) demonstrate high plasma von Willebrand factor levels 10,18 which does not appear to be present in patients with milder elevations of blood pressure. 7, 8 Although endothelial dysfunction or damage can be present as a result of hypertension, others have even considered that endothelial damage may actually promote hypertension.
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Association with the complications of hypertension
The common complications of hypertension can also be related to a prothrombotic state. For example, hypertension is a common cause of atrial fibrillation 20 and indeed, is additive to the risk of stroke and thromboembolism with this arrhythmia. 21 Atrial fibrillation per se is also well-recognised to be associated with abnormalities of haemostasis and endothelial dysfunction, which are altered by cardioversion and antithrombotic therapy, and are independent of underlying aetiology or structural heart disease. 22 Hypertension is an important cause of heart failure 23 and the evidence also points towards a hypercoagulable state in heart failure. 24 Indeed, heart failure is an important contributor to stroke and thromboembolism, with an inverse relationship between ejection fraction and stroke in the Survival and Ventricular Enlargement (SAVE) study; there was an 18% increase in stroke risk for every 5% reduction in left ventricular ejection fraction, thus clearly relating thromboembolism to severe cardiac impairment and the severity of heart failure.
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Association with prognosis
Mounting evidence of the prognostic value of these markers raises the possibility that they are not merely markers or consequences of atherothrombotic disease, but may contribute to the pathogenesis of hypertension and its complications. Indeed various indices are predictive of outcome in hypertension.
For example the Leigh general practice study reported that hypertensive subjects with plasma fibrinogen levels Ͼ3.5 g/l had a 12-fold higher cardiovascular risk than those with plasma fibrinogen levels Ͻ2.9 g/l. 15 Blann et al 26 suggested that high von Willebrand factor levels had prognostic value in hypertension, being predictive of cardiovascular disease progression. The study by Agewall et al 12 found that prothrombin fragment 1+2 and C-reactive protein were independent predictors of major coronary events. Our recent study also suggested that patients with hypertension who developed cardiovascular or cerebrovascular events at 4 years' followup had higher baseline vWf and fibrin D-dimer levels compared to those without events, although on Cox multivariate proportional hazards analysis only plasma fibrinogen and blood pressure levels emerged as independent predictors. 13 The possibility therefore remains that some prothrombotic indices, either individually or combination, may provide sufficiently high predictive value for cardiovascular disease and stroke. Further prospective studies on large cohorts would be required to confirm this hypothesis.
Effects of treatment
Treating hypertension may reduce the prothrombotic state. Indeed, antihypertensive agents with particular benefits in the hypercoagulable state in hypertensives would be likely to have additional advantages in reducing stroke and other thromboembolic events. For example, treated hypertensives demonstrate normal von Willebrand factor levels. 18 However, different drugs may affect the prothrombotic state differently (as reviewed by Lee 6 ). For example, drugs such as beta-blockers or calcium antagonists may have favourable haemorheological actions. In contrast, diuretics may have the opposite effect in increasing blood viscosity. 27, 28 These differences may in part explain some of the differences between different antihypertensive agents in the reduction of endpoints in some trials of antihypertensive therapy. For example, thiazides are beneficial in older hypertensives (over betablockers and placebo) in reducing stroke and cardiac events. 29, 30 In contrast, hypertensive patients on diuretic therapy have an increased mortality if electrocardiographic abnormalities (including LVH) are present. 31 Another example is isolated systolic hypertension, which was regarded as a 'different' disease from conventional systolic-diastolic hypertension. Indeed, most epidemiological and treatment studies have concentrated on diastolic blood pressures, whilst it has been recognised that systolic blood pressure is a better predictor of cardiovascular events. 32, 33 Furthermore, recent trials have confirmed the value of treating isolated systolic hypertension. 34, 35 Indeed data from the Syst-Eur study demonstrates how devastating isolated systolic hypertension can be, in terms of the number of thrombosis-related complications (that is, strokes and heart attacks) in the placebo group, which was reduced by antihypertensive therapy. This has led to recent appeals for the abandonment of the measurement of diastolic blood pressure. 36 Both isolated systolic hypertension and systolic-diastolic hypertension have been shown to be associated with abnormalities of haemorheology, thrombogenesis and endothelial dysfunction, as well as having similar echocardiographic parameters and left ventricular mass index, in keeping with both disease processes being similar in pathophysiology.
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Cause or effect?
It is likely that a continuum exists between normality, 'statistically increased' levels of haemostatic markers and overt thrombosis. If so, it is also likely that those with high levels of haemostatic markers are predictive of subsequent thromboembolic events, which has been borne out by recent published evidence. Indeed, other haemostatic markers have been shown to have prognostic implications in patients with ischaemic heart disease and peripheral arterial disease. 37 Nevertheless this raises the question whether the abnormal prothrombotic indices are 'cause or effect' with regard to cardiovascular disease. Whilst elevated plasma levels of a prothrombotic state are consistently associated with various cardiovascular disorders (coronary, cerebrovascular and peripheral artery disease) and the risk of vascular events, it has been suggested that these associations may be explained by a reactive or secondary rise in these plasma haemostatic factors, either as an acute phase response or as an atherosclerosis-related 'haematological stress syndrome'. 38 Since the processes of thrombogenesis and atherogenesis have certain similarities to inflammatory disease, the elevations in various indices may reflect the severity of vascular disorders as a secondary phenomenon rather than act as a true prognostic factor.
The hereditary determination of levels of some clotting markers makes it less likely that raised levels are simply a secondary response to cardiovascular disorders. For example, raised plasma levels of some indices, such as fibrinogen and vWf are also known to precede cardiovascular events. In addition, there is also an association between plasma fibrinogen or vWf levels with the clinical severity of angina or degree of coronary artery disease. 39 High levels of markers such as vWf are found following endothelial injury by smoking, hypertension or hyperlipidaemia. 40 There is also experimental evidence that some prothrombotic indices may be increased by glucocorticoids and cytokines such as interleukin-1 and tumour necrosis factor (TNF) which are produced by monocytes and macrophages. 41, 42 However, since some clotting factors are also acute phase proteins, increased levels may simply reflect endothelial activation or stimulation, and not endothelial dysfunction. The precise mechanisms for the elevated levels of various Journal of Human Hypertension prothrombotic markers in hypertension and other cardiovascular disorders therefore remain uncertain, although a cytokine-mediated increase in synthesis is likely to be the common pathway.
Conclusion
Whilst the blood vessels are exposed to high pressures in patients with hypertension, the main complications related to hypertension (that is, heart attacks and stroke) are paradoxically thrombotic in nature. Hypertension appears to confer a prothrombotic or hypercoagulable state, which can be related to target organ damage, long-term prognosis and treatment. Further work is needed to examine the mechanisms leading to this phenomenon, the potential prognostic and treatment implications, and the possible value of measuring these parameters in routine clinical practice. This new millennium may provide the answers.
